Goldman Sachs raised the firm’s price target on Nuvalent (NUVL) to $135 from $120 and keeps a Buy rating on the shares. Neladalkib continues to show best-in-class efficacy vs. other anaplastic lymphoma kinase tyrosine kinase inhibitors in refractory patients, the analyst tells investors in a research note. The firm continues to believe Nuvalent could seek NCCN guideline recommendations for neladalkib in 1L ALK+ NSCLC ahead of its approval there following a similar strategy for zidesamtinib in 1L ROS1+ NSCLC.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $155 from $125 at Guggenheim
- Nuvalent price target raised to $158 from $112 at Baird
- Nuvalent’s Neladalkib Shows Superior Efficacy and Safety in Clinical Trials
- Nuvalent announces $500M Class A common stock offering
- Nuvalent price target raised to $152 from $112 at Barclays